Trade PharmaCyte Biotech, Inc. - PMCB CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.13 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.026235% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.004012% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 1.78 |
| Open | 1.75 |
| 1-Year Change | -27.39% |
| Day's Range | 1.71 - 1.93 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Sep 13, 2024 | 1.88 | 0.13 | 7.43% | 1.75 | 1.96 | 1.66 |
| Sep 12, 2024 | 1.78 | 0.06 | 3.49% | 1.72 | 1.79 | 1.72 |
| Sep 11, 2024 | 1.74 | 0.18 | 11.54% | 1.56 | 1.80 | 1.56 |
| Sep 10, 2024 | 1.64 | 0.13 | 8.61% | 1.51 | 1.69 | 1.50 |
| Sep 9, 2024 | 1.52 | -0.01 | -0.65% | 1.53 | 1.73 | 1.42 |
| Sep 6, 2024 | 1.57 | 0.12 | 8.28% | 1.45 | 1.67 | 1.45 |
| Sep 5, 2024 | 1.57 | 0.08 | 5.37% | 1.49 | 1.59 | 1.49 |
| Sep 4, 2024 | 1.49 | -0.01 | -0.67% | 1.50 | 1.52 | 1.48 |
| Sep 3, 2024 | 1.44 | -0.04 | -2.70% | 1.48 | 1.50 | 1.44 |
| Aug 30, 2024 | 1.51 | 0.01 | 0.67% | 1.50 | 1.52 | 1.48 |
| Aug 29, 2024 | 1.51 | 0.00 | 0.00% | 1.51 | 1.57 | 1.51 |
| Aug 28, 2024 | 1.48 | 0.09 | 6.47% | 1.39 | 1.51 | 1.39 |
| Aug 27, 2024 | 1.48 | -0.09 | -5.73% | 1.57 | 1.57 | 1.36 |
| Aug 26, 2024 | 1.53 | -0.06 | -3.77% | 1.59 | 1.67 | 1.50 |
| Aug 23, 2024 | 1.61 | -0.12 | -6.94% | 1.73 | 1.75 | 1.61 |
| Aug 22, 2024 | 1.78 | 0.00 | 0.00% | 1.78 | 1.78 | 1.76 |
| Aug 21, 2024 | 1.81 | 0.03 | 1.69% | 1.78 | 1.81 | 1.75 |
| Aug 20, 2024 | 1.78 | -0.01 | -0.56% | 1.79 | 1.83 | 1.77 |
| Aug 19, 2024 | 1.83 | 0.04 | 2.23% | 1.79 | 1.87 | 1.79 |
| Aug 16, 2024 | 1.83 | 0.00 | 0.00% | 1.83 | 1.86 | 1.83 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
PharmaCyte Biotech, Inc. Company profile
About Pharmacyte Biotech Inc
PharmaCyte Biotech, Inc. is a clinical-stage biotechnology company. The Company is focused on developing cellular therapies for cancer and diabetes based upon a cellulose-based live cell encapsulation technology known as Cell-in-a-Box. Cell-in-a-Box technology is used as a platform upon which therapies for several types of cancer, including locally advanced, inoperable, non-metastatic pancreatic cancer (LAPC). The Company's lead product candidate, CypCaps is in Phase II of the clinical trials in LAPC. It also focused on developing a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes. Its product candidate for the treatment of diabetes consists of encapsulated genetically modified insulin-producing cells. The Company is also focused on the benefits of the Cell-in-a-Box technology to develop therapies for cancer that involve prodrugs based upon certain constituents of the Cannabis plant, such as cannabinoids.
Financial summary
BRIEF: For the nine months ended 31 January 2022, Pharmacyte Biotech Inc revenues was not reported. Net loss increased 9% to $2.8M. Higher net loss reflects General and administrative increase from $291K to $836K (expense), Legal and professional increase of 85% to $601K (expense), Director fees increase of 1% to $209K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$1.88 to -$0.74.
Equity composition
Common Stock $0.0001 Par, 03/11, 500M auth., 353,387,581 issd. Insiders own 9.09%. 12/03, 3 for 1 forward stock split. 03/09, Name changed from eFoodSafety.com Inc. Preferred Stock $.0001 Par, 10M auth., 5K issd.
| Industry: | Pharmaceuticals (NEC) |
3960 Howard Hughes Parkway, Suite 500
LAS VEGAS
NEVADA 89169
US
News
ECB Preview: cuts expected but the pace is uncertain
Markets expect the ECB to cut rates again in September, but how many more?
12:34, 11 September 2024
Market analysis: US CPI and PPI
Overview of upcoming US inflation data for August, with expectations for a year-over-year CPI drop to 2.6% and core CPI holding steady at 3.2%. Markets will also focus on U.S. PPI data, which is forecasted to show mild growth, reinforcing potential easing inflationary pressures.
07:56, 10 September 2024
Introducing Newsquawk: your new in-platform newsfeed
We are very excited to announce the launch of Newsquawk in the Capital.com platform and app. This new newsfeed is designed to help you get ahead with real-time headlines, personalised stories and in-depth reports – all available directly in the platform and app, where you need them.
14:09, 20 August 2024
Jackson Hole Preview: All eyes on Powell and Gold
The key focus this week will be on Jerome Powell and any insight he may give into the future of monetary policy.
15:24, 19 August 2024
All eyes on inflation: US and UK CPI take centre stage
Just over a month has gone by since the latest CPI data was released in the US and so much has happened since.
14:41, 13 August 2024
European stocks face resistance in their attempt to recover
European stocks struggle to recover as the tech sector faces continued downside pressure in Asia.
13:56, 9 August 2024
Global selloff continues on US economy fears
Thursday’s rise in jobless claims led to a market meltdown in the US stock market as investors became concerned that the Federal Reserve made the wrong decision by keeping rates unchanged on Wednesday.
14:40, 5 August 2024People also watch
Still looking for a broker you can trust?
Join the 640,000+ traders worldwide that chose to trade with Capital.com